Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
PaperCitations, authors & open-access status
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 578 citations, 2018 year and green oa status.
578
Citations
2018
Year
green
OA Status